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Abstract 
We previously demonstrated that the utilization of an electrospun scaffold could boost functional 
outputs of transplanted islets. In this study, we aim to develop a drug-eluting scaffold with a payload 
of pioglitazone to simultaneously rein in hyperglycemia and recoup lost renal functions in diabetic 
mice that underwent islet transplantation. The in vivo proliferation of islets was measured by a 
non-invasive bio-imaging technology whereas the blood insulin, blood glucose and renal proteins 
were assayed. The local stimulation of transplanted islets by pioglitazone saw an accelerated in vivo 
proliferation without apoptosis caused by the drug-eluting scaffold. In addition, pioglitazone 
contributed to an increased secretion of insulin and C-peptide 2, giving rise to an accelerated 
rein-in of hyperglycemia and enhanced tolerance of sudden oral glucose challenge. Moreover, the 
accelerated decrease of blood creatinine, urine creatinine and blood urea nitrogen suggested that 
pioglitazone contributed to the recovery of renal functions compromised by diabetes. Our bio-
engineering strategy effectively ameliorated hyperglycemia and associated nephrotic disorders, and 
shed a new light on an engineering approach to combat diabetes. 
Key words: pioglitazone; diabetes; islet transplantation; electrospinning; scaffolds. 
Introduction 
Diabetes and its associated diseases like renal 
artery stenosis have been leading cause of deaths 
around the world for decades. In spite of significant 
progress in diabetic research in the last decades, islet 
transplantation has remained a popular clinical solu-
tion for diabetic patients to restore insulin secretion 
and to alleviate the hyperglycemia. Recent research 
suggested that insulin-secreting pancreatic β-cells 
could increase their proliferation in response to an 
enhanced demand for insulin and physiological inju-
ries.[1-4] This discovery shed a new light on the 
therapeutic approach for diabetic patients by stimu-
lating β-cells in islets to control the blood glucose lev-
el. Unfortunately, clinical observations only presented 
a very limited number of supportive case reports with 
the majority of patients demonstrating insufficient 
capability to secret adequate insulin for blood glucose 
hemostasis.[5-9]  
Tissue engineering scientists have extensively 
explored how to employ biomaterials to engineer 
functional tissues to recoup lost or compromised 
functions.[10-15] However, unfortunately, efforts 
dedicated to diabetes remains scant. This deficiency 








tissue engineering scheme to improve existing treat-
ments of diabetes. In current clinical practice, har-
vested islets are freely injected into patients’ in-
trakidney capsule. It has been noted that transplanted 
islets suffered a poor survival rate due to a variety of 
reasons like local inflammation, effectively requiring 
to a large pool of islets at the time of transplantation. 
These limitations prompted us to employ an electro-
spun scaffold to boost the functional output of islet 
transplantation.[16] We demonstrated that the use of 
an electrospun scaffold helped to accelerate the 
growth of transplanted islets, increased the level of 
blood insulin, and improved the management of hy-
perglycemia. Pioglitazone, a member of the thiazoli-
dinedione drug family, is clinically used to enhance 
the tissue sensitivity to insulin in diabetic patient 
alone or with other drugs.[17] Our previous research 
demonstrated that pioglitazone, either alone or with 
other anti-diabetic drugs, was effective in alleviating 
hyperglycemia by stimulating pancreatic β-cells for 
increased secretion of insulin.[18] Unfortunately, 
pioglitazone causes a potent immuno-suppression 
effect in clinical treatment, rendering diabetic patients 
venerable for various complications. 
In light of these research findings and clinical 
challenges, we aim to functionalize our electrospun 
scaffold so that it is capable of locally delivering 
pioglitazone to transplanted islets. This local delivery 
would stimulate the production of insulin and thus 
lead to a better control of blood glucose in diabetic 
patients whereas renal functions could be simultane-
ously restored. Meanwhile, this targeted delivery 
would dramatically decrease the required dosage of 
pioglitazone and minimize adverse side effects asso-
ciated with pioglitazone. The success of this strategy 
would give physicians an alternative therapeutic so-
lution to cope with the complex situation in diabetic 
patients. 
Materials and Methods 
The scaffold fabrication and the morphological 
characterization 
The scaffolds were fabricated as reported pre-
viously.[16] To fabricate the non-eluting scaffold 
(NES), PGC (Advanced Inventory Management, 
Mokena, IL) and PCL (Absorbable Polymers, Bir-
mingham, AL) were dissolved (weight ratio of 1:3) in 
1,1,1,3,3,3-Hexafluoro-2-propanol (HFP) (Sigma Al-
drich, St. Louis, MO) to reach a total concentration of 
12% (w/v). 0.5 mL of the solution was electrospun 
through a 27 gauge blunt needle to a collection board 
distanced at 25 cm from the needle tip at 30 kV volt-
age. The feeding rate was 3 ml/hr. The NES scaffold 
was desiccated in vacuum for 24 hr prior to subse-
quent analyses. For drug-eluting scaffold (DES), 
pioglitazone (12mg/ml) were added to the polymer 
solution and incubated at room temperature until it 
was completely dissolved. The pioglitazone-polymer 
solution was then electrospun under the same condi-
tions as NES scaffolds. Scanning electron microscopy 
(SEM) was used to study the fiber morphology in re-
spective scaffolds. 
The creation of MIP-luc transgenic mice 
MIP-luc transgenic mice (C57BL/6 background) 
that were able to express the firefly luciferase due to 
transgene containing an MIP promoter fragment were 
generated as reported previously.[16, 19] Each 
C57BL/6 mouse received one dose of streptozotocin 
(STZ) (50 mg/kg) (Sigma Chemical, St. Louis, MO) by 
i.p. injection every two days for a total of five doses. 
Diabetes was confirmed when the blood glucose 
concentration exceeded 500 mg/dl for at least two 
consecutive days in the absence of fasting. 
The in vitro characterizations of electrospun 
scaffolds 
Respective scaffolds were incubated in cell 
media (2ml aliquots) at 37˚C and 5% CO2 for up to 4 
days and the in vitro kinetics of drug release was 
measured by a HPLC system equipped with a 
Symmetry C18 column (Waters Corporation) per 
manufacturer’s protocol. Desiccated circular DES and 
NES scaffolds (D = 6.5 mm) were plated into a 96-well 
tissue culture plate (TCP) and incubated with 70% 
ethanol for 15 min followed by a thorough rinse of 
sterile PBS. Syngeneic islets from MIP-luc transgenic 
C57BL/6 mice were harvested by an intra-ductal 
collagenase digestion (Roche, Indianapolis, IN) and 
purification by Ficoll gradient centrifugation (Sigma 
Aldrich, St. Louis, MO) as previously described.[20, 
21] Freshly collected islets were seeded (100 islet 
equivalents/scaffold) on the scaffold or directly on 
the bottom surface of TCP in islet growth media, and 
incubated for two days at 37°C with 5% CO2. The 
viability of the islet population was measured by the 
tetrazolium compound [3-(4,5-dimethylthiazol-2-yl)-5
-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetr
azolium,inner salt] (MTS) (Promega Corporation, 
Madison, WI) per the manufacturer’s protocol. 
Apoptosis was measured using a Caspase-Glo® 3/7 
assay kit per the manufacturer’s protocols (Promega, 
Madison, WI, USA). 
The transplantation and proliferation of islets 
DES and NES were fabricated as stated above, 
sterilized in 70% ethanol and washed in sterile PBS. 
Islets from MIP-luc mice were transplanted with ei-
ther DES or NES (100 islet equivalents/scaffold) un-
der the kidney capsule while the diabetic mice were 




anesthetized with vaporized isoflurance following the 
established protocol.[16] All mice were euthanized 8 
weeks after the transplantation. All experiments in-
volving animals was reviewed and approved by 
Shanghai Changzheng Hospital to ensure the welfare 
of laboratory animals. The proliferation of trans-
planted islets was measured by the Xenogen IVIS 200 
imaging system (Xenogen, Alameda, CA) at select 
time points after the transplantation as previously 
described.[16, 19] Briefly, after being fasted for 4 hr, 
the mice were anesthetized with vaporized isofluo-
rane and positioned on the side for the initial image 
acquisition. Thereafter, each mouse received 15 
mg/ml D-luciferin in sterile PBS (150 mg/kg) by i.p. 
injection. The bioluminescent image was capture at 14 
min after the injection. Image processing and biolu-
minescent measurement were performed using the 
Living Image Software (Xenogen). 
Immuno-staining of insulin-secreting cells after 
transplantation 
After the euthanasia, the kidney from each 
mouse containing transplanted islets were harvested 
and fixated in 10% formalin at 4°C for at least 24 hr. 
Then each sample was embedded in paraffin, sliced in 
4 µm thick and collected on charged glass slides. An-
ti-insulin antibody (Abcam, Cambridge, MA, USA) 
was used to stain the insulin-secreting cell in each 
sample. 
Functional output of transplanted islets 
A blood sample from each mouse was collected 
from the tail vein before the transplantation and then 
every two weeks until the euthanasia. No mice un-
derwent fasting before the blood collection. The con-
centrations of C-peptide 2 and insulin were measured 
by a rat/mouse C-peptide 2 ELISA kit (Millipore, 
Bellirica, MA) and a rat insulin ELISA kit (Crystal 
Chem Inc., Chicago, IL), respectively, per manufac-
turers’ protocols.[16] The blood glucose was meas-
ured with OneTouch Ultra glucometer (Lifescan, 
Johnson&Johnson, Milpitas, CA). The oral glucoe tol-
erance test (OGTT) was performed on week 8 after the 
surgery. After the mice had been fasted for 16 hr, each 
mouse received glucose solution prepared with sterile 
water (100 mg/ml) (Sigma Aldrich) by oral gavage (2 
g/kg). Blood glucose levels were measured using 
blood samples collected before the oral gavage (min 0) 
and at 30, 60 and 120 min after the gavage. The serum 
concentration of pioglitazone was measured at week 
0, 4 and 8 following established protocols.[22, 23] The 
Immunoassays & Multiplex Kits (EMD Millipore, 
Billerica, MA) were used to measure plasma cyto-
kines, including monocyte chemoattractant protein-1 
(MCP-1), interlukin-6 (IL-6) and interferon gamma 
(IFNγ), per the manufacturer’s protocol at week 0, 4 
and 8. 
Renal function recovery after the isle 
transplantation 
Blood and urine samples were collected imme-
diately before the transplantation and then every two 
weeks after the surgery until the euthanasia. Blood 
creatinine (Abcam, Cambridge, MA), blood urea ni-
trogen (Bio Scientific Corp, Austin, TX), urine creati-
nine (Abcam) and urine albumin (Abnova, Walnut, 
CA), were assayed following manufacturers’ proto-
cols as reported before. 
Data Analysis 
Images were processed with ImageJ. Student 
t-test with a Tukey test was used to analyze all data 
(α=0.05). All results were presented as mean ± stand-
ard deviation. 
Results 
The characterizations of the DES scaffold 
The SEM micrographs showed no marked dif-
ference of fiber morphology between DES and NES 
groups (Figure 1). Our previous research demon-
strated that the use of an electrospun PCL/PGC 
composite scaffold could lead to an improved man-
agement of blood glucose in diabetic mice due to the 
increased insulin from transplanted islets.[16] Those 
results suggested that the PCL/PGC scaffold pro-
vided a favorable microenvironment for islets to sur-
vive and proliferate without introducing cytotoxicity 
into the host. The lack of fiber morphology between 
DES and NES suggested that the enhanced functional 
output should be attributed to the therapeutic effects 
of pioglitazone, rather than structural cues from the 
scaffolds. 
The in vitro kinetic study showed that pioglita-
zone saw a sustained release from DES for up to 4 
days (Figure 2A). By day 4, the accumulative release 
of pioglitazone reached 96.00±24.44% and saw no in-
crease beyond day 4. No pioglitazone was detected in 
the NES group (negative control). In the DES scaffold 
group, the serum concentration of pioglitazone 
reached 0.89±0.16 µg/ml at week 4 and dropped to 
0.14±0.12 µg/ml at week 8 (Figure 2B). No pioglita-
zone were detected in the NES scaffold group. Neither 
MTS assay nor the apoptosis assay showed a differ-
ence among the NES, DES and TCP groups, suggest-
ing that scaffolding materials and pioglitazone did 
not cause a significant apoptosis or jeopardized the 
viability of islets (Figure 2C and 2D). 





Figure 1. The SEM micrographs of scaffolds. (A) non-eluting scaffolds (NES); (B) drug-eluting scaffolds (DES). No morphological difference was observed 
between NES and DES scaffolds. This result suggested that the difference of biomedical functional outputs was attributed to pioglitazone. 
 
 
Figure 2. The characterizations of DES scaffolds. (A) The in vitro release of pioglitazone (n=3). (B) The concentration of pioglitazone in serum (n=8 in DES 
group; n=7 in NES group). (C) The viability of islets cultured on DES, NES and tissue culture plates (TCP) (n=3); (D) The apoptosis in islets cultured on DES, 
NES and TCP (n=3). The DES scaffold could readily release pioglitazone for a limited time and exhibited no cytotoxic effects on islets. 
 
The in vivo proliferation of islet transplants 
The quantification of bioluminescent signal 
strength showed that the proliferation of islets accel-
erated in the presence of pioglitazone (Figure 3). The 
islet population from the DES group outgrew its peer 
from the NES group as early as week 4 and sustained 
this proliferative advantage through week 8. The bi-
oluminescent signal strength of the DES group was 
43.59% and 34.93% larger than that of the NES group 
on week 4 and 8, respectively. This sustained prolif-
eration spoke to the fact that pioglitazone accelerated 
the growth of transplanted islets without provoking 
adversary effects like significant apoptosis. 
The functional outputs of transplanted islets 
The immunostaining demonstrated that pockets 
of viable insulin-secreting cells were under the in-
trakidney capsule by the end of week 8, evidencing 
that transplanted islets survived and reestablished 
their most critical function, that is, the insulin secre-
tion (Figure 4). At week 4 after the surgery, the 
C-peptide 2 concentrations from the DES and NES 
groups were 45.81±6.01 pM and 30.33±6.23 pM, re-
spectively. Correspondingly, the insulin concentra-
tions from the DES and NES groups were 
239.23±30.11 pg/ml and 152.11±32.91 pg/ml, respec-
tively. Both C-peptide 2 and insulin showed a signif-
icant increase in the DES group at week 4 and this 
increase was observed through week 8 (Figure 5). 
Thanks to the increased insulin production in the DES 
group, the blood glucose level in the DES group re-
turned to the physiological range (<300mg/dl) on 
week 3 (257.56±40.21mg/dl) and remained through 
week 8 (213.45±27.45mg/dl). In contrast, the blood 
glucose level in the NES group remained abnormally 




high at week 4 (362.11±49.45mg/dl) and only entered 
the physiological range on week 8 
(273.45±35.67mg/dl) (Figure 6A). The OGTT assay 
demonstrated that pioglitazone stimulated islets un-
leashed an enhanced tolerance to glucose challenge 
(Figure 6B). At 30 min after the glucose challenge, 
mice from the DES group showed a blood glucose 
concentration of 317.22±49.99mg/dl whereas those 
from the NES group of 421.59±41.34mg/dl. Moreover, 
the glucose level in the DES group returned to physi-
ological level by 60 min after the challenge 
(227.56±40.21mg/dl) whereas the glucose level in the 
NES group remained abnormally high 
(338.92±32.11mg/dl) by 120 min. These results 
demonstrated that transplanted islets successfully 
survived and recapitulated their functions. Moreover, 
the stimulation of pioglitazone further enhanced the 
secretion of insulin and thus yielded an accelerated 
elimination of hyperglycemia compared to 
non-stimulated subjects. 
 
Figure 3. The in vivo proliferation of islets. (A) The strength of bioluminescent signals; (B) Representative bioluminescent images. The islets in the DES 
group outgrew those in the NES group ever since week 4 and maintained the lead through week 8. This result suggested that pioglitazone caused a late yet 
long-term therapeutic effect rather than an immediate one. A star sign indicates a statistical difference between the groups (n=8 in the DES group; n=7 in 
the NES group). 
 
Figure 4. Insulin-secreting cells. (A) islet transplant from NES group; (B) islet transplant from DES group. The immuno-staining showed that islet trans-
plants in both groups possessed their insulin-secreting capability. Arrows indicate the islet transplant in respective images. 
 
Figure 5. The insulin production by transplanted islets. (A) C-peptide 2; (B) Blood insulin. Both C-peptide 2 and insulin concentrations were higher in the 
DES group since week 4. These results suggested that pioglitazone contributed to the increase of insulin secretion. A star sign indicates a statistical 
difference between the groups (n=8 in the DES group; n=7 in the NES group). 





Figure 6. Hyperglycemia alleviation. (A) Blood glucose concentrations; (B) OGTT. The decrease of blood glucose concentration in the DES group 
outpaced that in the NES group. A marked difference emerged since week 4. Consequently, mice in the DES group demonstrated a stronger tolerance of 
sudden glucose spike. These results suggested that pioglitazone contributed to the management of blood glucose. A star sign indicates a statistical difference 
between the groups (n=8 in the DES group; n=7 in the NES group). 
 
The recovery of renal functions 
The concentrations of blood creatinine, urine 
albumin, blood urea nitrogen and urine creatinine are 
routinely used to assess the renal functions in diabetic 
subjects.[16] Following the islet transplantation, con-
centrations of all four proteins in both DES and NES 
group saw a steady decrease through week 8 (Figure 
7). It is noteworthy that blood creatine, blood urea 
nitrogen and urine creatine in the DES group demon-
strated an accelerated decrease compared to those in 
the NES group. At week 2, the concentrations of blood 
creatinine in the DES and NES groups were 1.42±0.27 
mg/dl and 1.98±0.21 mg/dl, respectively, whereas the 
concentrations of urine creatinine were 155±18 mg/dl 
and 211±24 mg/dl, respectively. Similarly, the con-
centrations of blood urea nitrogen in the DES and 
NES groups were 48.99±12.11 mg/dl and 78.31±11.34 
mg/dl, respectively, at week 2. However, the acceler-
ated decrease of blood and urine creatinine in the DES 
group was lost by week 6 while that of blood urea 
nitrogen by week 4. No marked difference of urine 
albumin concentrations between DES and NES 
groups were observed at any time points. These re-
sults suggested that pioglitazone might have contrib-
uted to the accelerated renal function recovery in di-
abetic subjects. The concentrations of plasma cyto-
kines, including MCP-1, IL-6 and IFNγ, showed no 
significant difference between DES and NES groups 
over the course of 8 weeks (Figure 8). 
Discussion 
Electrospun scaffolds have been extensively 
studied to acquire the capability of delivering thera-
peutic molecules to local tissues for an improved tis-
sue regeneration.[24, 25] Illuminated by previous re-
search, here we functionalized our electrospun scaf-
fold to deliver pioglitazone to local islets in the hope 
of further enhancing the therapeutic effectiveness by 
reining in the hyperglycemia and the loss of renal 
functions. Previous research discovered that 
pioglitazone could prevent the apoptosis of islets, the 
onset of streptozotocin-induced diabetes and dys-
function of pancreatic β-cells.[26-28] SEM micro-
graphs showed no marked difference of fiber mor-
phology between DES and NES scaffolds, evidencing 
that the incorporation of pioglitazone would not in-
troduce structural changes to the scaffold. This lack of 
structural change ensured that the enhanced func-
tional output of transplanted islets derived from the 
pharmaceutical capability of pioglitazone. The in vitro 
kinetic study showed that the DES readily released 
pioglitazone into the milieu within a 4-day window. 
This rapid and sustained release would subject the 
transplanted islets to a sufficient yet temporary stim-
ulation, which could minimize unwanted side effects. 
Meanwhile, the in vivo analysis showed that 
pioglitazone remained in the blood circulation at 
week 4 but got cleared by week 8. This further at-
tested the temporary nature of this pioglitazone 
therapy scheme. Moreover, the MTS result evidenced 
that islets retained their viability on DES scaffolds. 
Nor did the DES scaffold triggered massive apoptosis. 
These results together pointed out that DES scaffold 
was a biocompatible delivery vehicle for the rapid yet 
temporary release of pioglitazone to local islets. 
The bioluminescent measurement demonstrated 
a steady proliferation of transplanted islets in both 
DES and NES groups. The fact that the islet popula-
tion in the DES group outgrew its peer in the NES 
group, starting from week 4, suggested that the stim-
ulation by pioglitazone might have contributed to this 
proliferative advantage. It should be noted that the 
strength of the bioluminescent signal was positively 
associated with the mass of the islet population.[19] 
The immuno-staining also confirmed that trans-
planted islets in both groups contained insu-
lin-secreting cells, confirming that transplanted islets 
were fully functional. To quantitatively compare the 
insulin secretion capability between DES and NES 
groups, we measured the blood concentrations of 




C-peptide 2 and insulin. Both C-peptide 2 and insulin 
secretions saw an increase in the DES group as early 
as week 4, which could be attributed to the acceler-
ated proliferation of transplanted islets. Although it is 
a byproduct of insulin production with no known 
biological functions, C-peptide 2 serves as an im-
portant clinical indicator of functional output of islet 
transplantation because only endogenous insulin se-
cretion would give rise to C-peptide production. The 
fact that both C-peptide and insulin levels in the DES 
group was higher than those in the NES group since 
week 4 suggested that the stimulation of pioglitazone 
boosted the insulin secreting capability of trans-
planted islets, possibly by targeting pancreatic β-cells 
in the islets because they are responsible for insulin 
production.[29] The increased insulin secretion in the 
DES group readily translated into a decreased blood 
glucose level, showing that an enhanced insulin se-
cretion could alleviate the hyperglycemia in diabetic 
mice. Moreover, the mice in the DES group showed a 
stronger capability to withstand sudden glucose 
challenge, giving evidence to another benefit of the 
pioglitazone stimulation. These results demonstrated 
that the delivery of pioglitazone by an electrospun 
scaffold to local islets would be a promising means to 
manage the blood glucose level in diabetic patients 
following the islet transplantation. 
Renal functions are frequently compromised or 
lost due to diabetes, necessitating a kidney trans-
plantation. Since kidney transplantation is not readily 
available, a strategy allowing the recovery of renal 
functions is of great significance. Our results demon-
strated that the recovery of renal functions could be 
accelerated due to the pioglitazone stimulation. The 
levels of blood creatinine, urine creatinine, blood urea 
nitrogen and urine albumin all witnessed a drop over 
the 8-week window, suggesting an improved renal 
functions following the islet transplantation. Particu-
larly, blood and urine creatinine in the DES group 
demonstrated an accelerated decrease on week 2 and 
4, evidencing the therapeutic effect of the pioglitazone 
stimulation. These results suggested that the 
pioglitazone stimulation causes a synergistic effect in 
the treatment of diabetes, reigning in both the hyper-
glycemia and nephrotic disorders in diabetic subjects. 
In diabetic patients, the administration of pioglitazone 
frequently causes renal edema, a common culprit for 
nephrotic disorder, and mandates a cease of treat-
ment. Guan et al demonstrated that pioglitazone 
could cause renal edema due to an enhanced renal 
Na+ absorption via an ENaC mediated pathway.[30] 
This discovery suggested that pioglitazone might 
have the ability to impact renal tissues directly and 
argued for a revamped scheme for pioglitazone-based 
treatments for clinical benefits. Our results demon-
strated that a reduce dosage of pioglitazone delivered 
by a DES scaffold could relieve moderate renal injury. 
This would offer an easy to implement engineering 
solution for a clinical challenge. 
 
Figure 7. The recovery of renal functions. (A) blood creatinine; (B) urine albumin; (C) blood urea nitrogen; (D) urine creatinine. The creatinine con-
centrations in both blood and urine from the DES group were lower than those from the NES group on week 2 and 4. In addition, a difference was observed 
in blood urea nitrogen on week 2 between DES and NES groups. This accelerated recovery of blood creatinine, urine creatinine and blood urea nitrogen 
evidenced the therapeutic effect of pioglitazone on renal functions. A star sign indicates a statistical difference between the groups (n=8 in the DES group; 
n=7 in the NES group). 
 





Figure 8. Plasma cytokine concentrations. (A) MCP-1; (B) IL-6; (C) IFNγ. No significant difference was observed between DES and NES groups (n=8 in 
DES group; n=7 in NES group). 
Conclusion 
The stimulation of transplanted islets to achieve 
a blood glucose hemostasis in diabetic patients has so 
far witnessed limited clinical success. In our previous 
studies, we successfully boosted the insulin secretion 
of transplanted islets with an electrospun scaffold, 
which could be attributed to a more favorable mi-
croenvironment, to manage blood glucose in diabetic 
mice. In light of recent discovery on therapeutic roles 
of pioglitazone on diabetes, in this study we func-
tionalized the scaffold to be able to locally deliver 
pioglitazone to transplanted islets. The local stimula-
tion of transplanted islets by pioglitazone resulted in 
an accelerated islet growth, an increased insulin se-
cretion and consequently a lower blood glucose level 
in diabetic mice. Moreover, the alleviation of hyper-
glycemia also contributed to the recovery of renal 
functions compromised by the diabetes. These find-
ings shed new lights on the bioengineering of thera-
peutic devices for diabetic patients in the future. 
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